Current Cardiovascular Clinical Trials
Synopsis: The APPROPRIATE study will compare differences in functional capacity (peak VO2) between chronotropically incompetent patients randomized to receive rate responsive pacing driven by either the minute ventilation (respiration-based) sensor or an accelerometer (motion based).
Synopsis: The MADIT-CRT trial is designed to determine if combined implantable cardiac defibrillator (ICD)-cardiac resynchronization therapy (CRT-D) will reduce the risk of mortality and heart failure (HF) events by approximately 25%, in subjects who are in New York Heart Association (NYHA) functional Class II with non-ischemic or ischemic cardiomyopathy and subjects who are in NYHA functional Class I with ischemic cardiomyopathy, left ventriuclar dysfunction (ejection fraction [EF] < or = 0.30), and prolonged intraventricular conduction (QRS duration > or = 130 ms).
MADIT - RIT
Synopsis: The purpose of the MADIT-RIT trial is to compare the occurence of inappropriate therapy using high rate cutoff and/or long delay in primary prevention patients receiving and ICD or CRT-D device compared to standard programming.
Synopsis: The objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF>3 hours too < 7 days), symptomatic atrial fibrillation, and no evidence or history of congestive heart failure (CHF).
Tailored Treatment of Permanent Atrial Fibrillation (TTOP AF)
Synopsis: The purpose of this study is to evaluate the safety and efficacy of the Ablation Frontiers Cardiac Ablation System compared to currently approved treatment options for atrial fibrillation.
PARACOR PEERLESS HF
Synopsis: The purpose of this study is to determine if patients in the HeartNet Ventricular Support System with optimal medical and device therapy arm (Treatment group) show statistically significant improvement compared to patients in the optimal medical and device therapy alone arm (Control group) after 6 months of follow-up.
Synopsis: A randomized multicenter, double blind, group-sequential study to evaluate the efficacy , immunogenicity, and safety of a single dose of Merck 0657nI Staphylococcus Aureus Vaccine (V710) in adult patients scheduled for cardiothoracic surgery.
Synopsis: Heart disease and heart attacks pose a serious health risk to young women, and women tend to experience less successful recoveries after a heart attack than men do. This study will examine various factors that may predispose women to heart attacks and to poor recovery after a heart attack. The differences between men and women in the medical care that they receive following a heart attack will also be studied.